In Brief: Incstar
This article was originally published in The Gray Sheet
Incstar: Receives 510(k) clearance for a first generation complement activation enzyme (CAE) assay used to provide "general information about the immune system in certain disease states," including systemic lupus erythematosus, rheumatic disorders, "certain rare connective tissue disorders and massive tissue injury." The Stillwater, Minnesota-based immunodiagnostics firm says its CAE kit offers: "one year stability compared to two weeks" with competitors' products, the capability of performing large volume testing "in less than three hours," and reduced "hands on time in assay performance"...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.